ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / EOLS
CTMX (14) OVID (40) MPLT (35) PHAT (34) ⌘ Pro Terminal β†’

Evolus Inc. (EOLS) β€” RQD Stock Rating Cockpit

$7.35 -2.26% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.31

Evolus Inc. (EOLS) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record Warning: Scores below 50 (27/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows β†’
ROARABLE E β€’ RED ALERT Cap $496.7M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EOLS Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is EOLS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Evolus Inc. (NASDAQ: EOLS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $7.35 (-2.26% 1D, market cap $496.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EOLS ranks #923 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does EOLS compare to CTMX and OVID in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EOLS carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 66.3%, and ROIC of -35.0%. By comparison, CTMX (CytomX Therapeutics Inc.) holds a E grade (14/100 RQD, P/E N/A, ROIC -20.5%, cap $499.0M) and OVID (Ovid Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -28.5%, cap $500.0M). Among the 5-stock peer group, EOLS leads on earnings multiple (N/A) while CTMX leads on capital efficiency (-20.5% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EOLS?
β–Ό

Per EOLS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001570562), Evolus Inc. generated $297.2M in revenue (+11.6% YoY), -$51.6M in net income, and -$45.7M in free cash flow against $225.9M in total assets and $146.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.31 (-0.60%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 3/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (27/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510027
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk E
Cash (3)Whales (10)SEC (5)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14% Base Target
$10 Bull$6 Base$5 Bear
πŸ“¬ FREE EOLS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for EOLS)Realized 20D OHLCV Swing Band: Β±9.6%
Deterministic 5-Pillar Attribution (27/100 Composite)
πŸ” WHY EOLS SCORES 27/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+10/20 pts (37% of score)

20D Institutional Volume Accumulation (Β±9.6% realized swing band)

β–² #2 Bullish Driver: Macro Regime Fit+7/20 pts (26% of score)

FRED Regime Γ— Technicals: 64% of 52W Range β€’ RSI-14 at 49.6 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
35
Grade E$7.75-5% Next Q
Q2 (-2Q)
32
Grade E$7.36-2.6% Next Q
Q3 (-1Q)
30
Grade E$7.17+2.5% Next Q
Current
27
Grade E$7.35-10.3% Hist 90D Ξ±
Trajectory: E (35) β†’ E (27)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a EOLS Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While EOLS currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.96) and Max Pain ($7.72) forces dealer call-delta covering toward $9.78.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EOLSβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œEOLS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 27%NO 73%Trade / Inspect Odds β†’
RSI-14 MOMENTUMNEUTRAL RANGE
49.630 Oversold Β· 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
0.20>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE64% OF RANGE
L: $4$7.35H: $9
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 2 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 13 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 12 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on EOLS

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (15)

-35.0% ROIC with 66.3% gross margin and -9.20% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (25)

Altman-Z 0.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (33)

13/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like EOLS
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EOLS)

  • βœ“Walkthrough of EOLS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
EOLS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +31.72%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-02O $7.63H $7.63L $7.35C $7.35VOL 789.2K
RES: $10.60SUP: $7.01SMA50: $7.96SMA200: $6.27
$9.63$8.30$6.97$5.65$4.32RES $10.60SUP $7.01$7.352026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EOLS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ EOLS Butterfly Map β†’ + Track EOLS β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +11.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EOLS today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for EOLS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EOLS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EOLS)

Health Care Rank #923 of 1016 βš”οΈ CTMX vs EOLS Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (EOLS vs. CTMX, OVID, MPLT, PHAT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Evolus Inc. (EOLS) ranks #923 by composite RQD confidence (27/100, grade E) and #455 by equity capitalization ($496.7M). Within this direct 5-issuer industry benchmark cohort, EOLS leads on earnings valuation at N/A trailing P/E, while CTMX leads on capital efficiency and profitability with -20.5% ROIC and β€” gross margin. OVID currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with EOLS at 27/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
EOLS ACTIVE
Evolus Inc.
E 27/100 β€” 66.3% -35.0% -2.26% $496.7M Benchmark Subject
CTMX
CytomX Therapeutics Inc.
E 14/100 β€” β€” -20.5% +2.18% $499.0M /ctmx-vs-eols β†’
OVID
Ovid Therapeutics Inc.
D- 40/100 β€” β€” -28.5% -0.78% $500.0M /ovid-vs-eols β†’
MPLT
MapLight Therapeutics Inc.
D- 35/100 β€” β€” -32.4% -1.81% $500.1M /mplt-vs-eols β†’
PHAT
Phathom Pharmaceuticals Inc.
E 34/100 β€” 87.1% -35.0% -7.72% $503.2M /phat-vs-eols β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001570562

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Evolus Inc. (EOLS) reported GAAP revenue of $297.2M (+11.6% vs. FY2024 revenue of $266.3M , and +47.1% cumulative change since FY2023) , GAAP net income of -$51.6M, operating cash flow of -$42.3M, and free cash flow of -$45.7M (-134.7% YoY). On the balance sheet, EOLS closed FY2025 with $225.9M in total assets against $146.1M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $297.2M -$51.6M -$42.3M -$45.7M $225.9M $146.1M
FY2024 (FY) 2024-12-31 $266.3M -$50.4M -$18.0M -$19.5M $232.6M $121.5M
FY2023 (FY) 2023-12-31 $202.1M -$61.7M -$34.0M -$34.0M β€” β€”

3. EOLS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EOLS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Evolus Inc. (NASDAQ: EOLS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $7.35 (-2.26% 1D, market cap $496.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EOLS ranks #923 in composite RQD confidence.

How does EOLS compare to CTMX and OVID in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EOLS carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 66.3%, and ROIC of -35.0%. By comparison, CTMX (CytomX Therapeutics Inc.) holds a E grade (14/100 RQD, P/E N/A, ROIC -20.5%, cap $499.0M) and OVID (Ovid Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -28.5%, cap $500.0M). Among the 5-stock peer group, EOLS leads on earnings multiple (N/A) while CTMX leads on capital efficiency (-20.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EOLS?

Per EOLS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001570562), Evolus Inc. generated $297.2M in revenue (+11.6% YoY), -$51.6M in net income, and -$45.7M in free cash flow against $225.9M in total assets and $146.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EOLS trading relative to its 50-day, 200-day, and 52-week technical levels?

EOLS last traded at $7.35 (-2.26% on volume of 794,435 shares), positioning the stock -7.66% below its 50-day simple moving average ($7.96) and +17.22% above its 200-day simple moving average ($6.27). Across its 52-week range of $3.86 to $9.31, EOLS sits at the 64.0% percentile with a 14-day RSI of 49.6 (NEUTRAL RANGE) and an implied next-earnings move of Β±9.6% ($6.64 to $8.06).

EOLS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Should I buy, hold, or sell EOLS stock right now?

Evolus Inc. (EOLS) currently earns a Roarable Rating of E (Strong Sell β€” SELL) with 27/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is EOLS's 12-month price target and RQD AI Jury consensus?

EOLS's 12-month base price target is $6.32 (range $4.93 to $9.78), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: EOLS RQD Cockpit EOLS 12M Forecast EOLS Earnings & Move EOLS Dividends & DRIP EOLS Insiders & 13F EOLS Whale Options EOLS Profit Sankey EOLS News & Why
ROARABLE RATING BRIEF β€’ RQD 27/100 (E) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

EOLS β€” Evolus Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:35:49Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, EOLS carries an RQD Score of 27 / E, labeled "Roarable Strong Sell β€” Forensic Risk / Avoid." The score is built from five pillars, each scored out of 20:

  • Fundamental Cash Engine: 2 / 20. Per the Roarable RQD rating, ROIC is -35% and FCF yield is -9.2%. This is the weakest pillar and indicates the business is not currently converting capital into cash returns. For a prospective investor, the upside case must rest on a future turn in operating economics rather than on current cash generation.
  • Whale 13F Flow: 10 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. It is the strongest pillar but still below mid-range, suggesting institutional interest is present without being decisive.
  • Insider Conviction: 3 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates insider and disclosed-trade signals provide little confirming support for the thesis.
  • Macro Regime Fit: 7 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. The stock moves in line with the market, offering no defensive cushion or macro tailwind identified in the source.
  • Forensic Balance Sheet: 5 / 20. Per the Roarable RQD rating, Altman Z is 0.2, Piotroski F is 4/9, and Debt/Equity is 0.5. The Altman Z reading is in a distress-associated range and is the key forensic risk flag.

Valuation tradeoffs are difficult to assess because P/E, Forward P/E, EV/EBITDA, and EPS (TTM) are not available in source data. The main upside driver implied by the data is the gap between a $7.52 price and a 52-week range of $3.86 - $9.31 combined with a 66.3% gross margin, which suggests pricing power at the gross level but is overwhelmed by operating losses (-11% operating margin). The investor implication is that any re-rating depends on operating leverage improving, which the current forensic profile does not yet evidence.

Business

Evolus Inc. (EOLS) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the SEC financials, the company generated revenue of $297.2M in FY 2025. The source data does not describe specific products, customer segments, or revenue model beyond the sector and industry classification. Per the profile, market capitalization is $0.5B.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$297.2M$-32.7M$-51.6MN/A$-45.7M$53.8M$146.1M
FY 2024$266.3M$-34.4M$-50.4MN/A$-19.5M$87.0M$121.5M
FY 2023$202.1M$-49.2M$-61.7MN/A$-34.0MN/AN/A

Per the SEC financials, revenue grew from $202.1M (FY 2023) to $297.2M (FY 2025), while net losses remained in the $-50M to $-62M range across all three periods. Per the market data, gross margin is 66.3%, operating margin is -11%, and net margin is -17.4%. Per the Roarable RQD rating, ROIC is -35% and the Altman Z-Score is 0.2, with a Piotroski F-Score of 4/9. Cash declined from $87.0M (FY 2024) to $53.8M (FY 2025) while debt rose from $121.5M to $146.1M, indicating a weakening balance sheet posture over the most recent year.

Recent Catalysts & News Wire Analysis

  • Earnings estimate: A TradingView item cites a Q3'26 revenue estimate of 77.58M USD. This is a forward-looking figure that will be a near-term reference point.
  • Legal/investigation notices: Multiple items (PR Newswire and The National Law Review) reference shareholder-claim investigations involving EOLS. These are flagged as YELLOW risk-watch items and warrant review of primary filings.
  • Positive signal: A Simply Wall St item referencing insider-backed growth stocks is flagged GREEN as a CATALYST, though the source does not detail the underlying insider activity.
  • Market wire: Five of six items are YELLOW market-wire notices with no quantitative content beyond headlines.
  • Butterfly Supply-Chain Graph: Not available in source data for this section; the graph reports no supply-chain links and no proprietary signals.

Open Questions

  • What are the P/E, Forward P/E, EV/EBITDA, and EPS (TTM) values, given that the Snapshot shows none are available?
  • What is the source and detail of the shareholder-claim investigations referenced in the news wire, and do they affect the balance sheet?
  • What drove the increase in debt from $121.5M to $146.1M alongside a decline in cash, and what is the repayment profile?
  • Which specific institutions and insiders underlie the whale 13F and insider conviction pillar scores?
  • What products and customer segments generate the $297.2M in revenue, and what is the path to positive operating income?

EOLS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Evolus Inc. (EOLS) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to EOLS Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EOLS Bull vs. Bear Conversation Board β€” What's Your Call at $7.35?

πŸ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EOLS 🐻 67% BEARISH CONVICTION
1. Pick Your Side on EOLS:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $6.62 (-12.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is EOLS (E β€’ RQD 27/100) a Buy at $7.52?

Welcome to the EOLS (Evolus Inc.) Roar Pit. Current RQD Composite is 27/100 (Roarable Strong Sell β€” Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $6.17 (-18.0%)
Spot @ $7.52

Pump the brakes on EOLS β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on EOLS, but look at what you are paying: current EV/EBITDA multiples with 66.3% gross margins. Unless Evolus Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $8.72 (+16.0%)
Spot @ $7.52

EOLS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on EOLS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $7.52 (52-wk range $3.86 - $9.31), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%